Last update Aug. 23, 2021
Likely Compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
C11 H17 N2 NaO3 is Pentobarbital Sodium in Molecular formula.
Is written in other languages:C11 H17 N2 NaO3 is also known as
C11 H17 N2 NaO3 belongs to these groups or families:
Main tradenames from several countries containing C11 H17 N2 NaO3 in its composition:
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Barbiturate with hypnotic and sedative properties similar to amobarbital.
It has been used in insomnia and as a preanesthetic medication. Its use has been replaced by other drugs with less risk of abuse/dependence, overdose and withdrawal syndrome (Suddock 2020).
Oral or parenteral administration.
It is excreted in breast milk in a clinically insignificant amount (Horning 1975, cited in Wilson 1980).
Product with very few bibliographic and very old references in relation to breastfeeding. Commercialized in few countries.
Until more published data on this drug is available in relation to breastfeeding, known safer alternatives may be preferable, especially during the neonatal period and in the event of prematurity.
See below the information of this related product: